Meghan Flaherty

Statistics

Publications

Citations

177

H-Index

Active since

2011

Affiliations

Novartis (Switzerland)(Current)

Novartis Institutes for BioMedical Research

Meghan Flaherty is an author at Novartis (Switzerland) specializing in pharmacology, differential gene expression, and species differences in toxicity.

Publications per year

2011–2025

Publications

Discovery and Optimization of HKT288, a Cadherin-6–Targeting ADC for the Treatment of Ovarian and Renal Cancers

Carl Uli Bialucha, Scott D. Collins, Xiao Li et al. · Cancer Discovery · 2017 · 55 citations · Full text

Medicine, Oncology, Pharmacology +15

Opportunities for use of one species for longer-term toxicology testing during drug development: A cross-industry evaluation

Helen Prior, Paul Baldrick, Sonja Beken et al. · Regulatory Toxicology and Pharmacology · 2020 · 40 citations · Full text

Pharmacy, Pharmacology, Toxicology +16

Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies

Beryl B. Cummings, Mark Joing, Page Bouchard et al. · The Lancet · 2025 · 36 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

Nonclinical Evaluation of GMA161—An Antihuman CD16 (FcγRIII) Monoclonal Antibody for Treatment of Autoimmune Disorders in CD16 Transgenic Mice

Meghan Flaherty, Timothy K. MacLachlan, Misty Troutt et al. · Toxicological Sciences · 2011 · 34 citations

Life Sciences, Immunology, Pathology +10

An ANGPTL4 inhibitory antibody safely improves lipid profiles in non-human primates

Beryl B. Cummings, Page Bouchard, Mark Milton et al. · EBioMedicine · 2025 · 12 citations · Full text

Medicine, Cardiology, Pharmacology +17

1–5 of 5